Mechanism of action of cariprazine.
نویسنده
چکیده
Cariprazine is a new therapeutic agent recently approved for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar disorder, and is under investigation for the treatment of both bipolar depression and major depressive disorder.
منابع مشابه
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
Background Cariprazine, a D3-preferring dopamine D2/D3 receptor partial agonist, is a new antipsychotic drug recently approved in the United States for the treatment of schizophrenia and bipolar mania. We recently demonstrated that cariprazine also has significant antianhedonic-like effects in rats subjected to chronic stress; however, the exact mechanism of action for cariprazine's antidepress...
متن کاملNew developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipolar disorder. Like risperidone, cariprazine improves positive and negative sch...
متن کاملClinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).
PURPOSE Cariprazine is a potent dopamine D3-preferring D3/D2 receptor partial agonist in development for the treatment of schizophrenia, bipolar mania, and depression. Pharmacokinetics of cariprazine and the two clinically relevant metabolites (desmethyl- and didesmethyl-cariprazine) was evaluated in a clinical pharmacology study. METHODS This was a multicenter, randomized, open-label, parall...
متن کاملCariprazine for Schizophrenia and Bipolar Disorder.
Schizophrenia and bipolar disorder are associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms of schizophrenia as well as manic or mixed episodes of bipolar disorder, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatme...
متن کاملCariprazine in bipolar disorders.
Key Study Findings The authors report a multicenter (N = 497), randomized, double-blind, placebo-controlled study (NCT01058668). Patients were randomly assigned to placebo, cariprazine 3–6 mg/d, or cariprazine 6–12 mg/d for 3 weeks. The primary outcome was change from baseline to week 3 utilizing the Young Mania Rating Scale (YMRS). Both cariprazine groups were statistically significantly super...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- CNS spectrums
دوره 21 2 شماره
صفحات -
تاریخ انتشار 2016